Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Supaglutide - Innogen Pharmaceutical Technology

Next Previous
Drug Profile

Supaglutide - Innogen Pharmaceutical Technology

Alternative Names: Diabegone; Efsubaglutide alfa; Efsubaglutide alfa - Innogen Pharmaceutical Technology; Supaglutide injection - Shanghai Innogen Pharmaceutical Technology

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St. Michaels Hospital; University of Toronto
  • Developer Yinnuo Pharmaceutical Technology
  • Class Antihyperglycaemics; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 31 Mar 2025 Shanghai Yinnuo Pharmaceutical Technology initiates enrolment in phase-II clinical trials in Obesity in China (SC) (NCT06921486)
  • 28 Mar 2025 Shanghai Yinnuo Pharmaceutical Technology plans a phase III trial for Type 2 diabetes mellitus in July 2025 (SC, Injection) (NCT06900075)
  • 18 Dec 2024 Phase-II clinical trials in Type 2 diabetes mellitus (In adults, In the elderly) in China (SC) (NCT06849843)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top